Search results

Selected filters:

News
Life Sciences

Article type

Topic

Sector

Regions

Year

147 results found for your search

Sort options
05 June 2015

US patent reform passes a key Congressional hurdle but still faces significant challenges

It is a truism of US politics that one of the hardest things in Washington DC is getting a bill to the floor of the Senate for a vote. In that respect patent reform took a major step forward yesterday as the PATENT Act, the bill introduced last…

25 May 2015

Patent reform could do terrible damage to our many successful programmes, says Columbia's tech transfer chief

Orin Herskowitz is head of technology transfer at Columbia University, one of the most respected and successful university licensing operations in the United States. His role not only means that he is plugged into the steady stream of new technology…

19 May 2015

It's not all doom and gloom for pharmaceutical innovators in India

Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet …

18 May 2015

The USPTO has the power to create a much more equitable IPR process; and it should do so

Since the America Invents Act overhauled the re-examination process, we have written regularly about the impact that the new procedures, and inter partes reviews in particular, have had on the patent market. Essentially, they have become a new tool…

15 May 2015

Compulsory licensing is not just a risk factor in India and other emerging markets

The following is a brief extract from a letter which a national legislator sent to a member of the cabinet earlier this week: “I ask you to utilise federal law… to break the patents on these drugs to authorise third parties to manufacture or…

08 May 2015

It’s not just big pharma that wants to see IPR reform in US patent legislation

For over an hour yesterday, as the Senate Judiciary Committee hearing on the recently introduced PATENT Act unfolded, it seemed like we were in patent fantasyland. Except for some predictable comments from the deputy general counsel of pharma giant…

08 May 2015

More evidence that Chinese patent values could rise as Apple win shows increasing court focus on quality

On the sidelines of the INTA annual meeting in San Diego, IAM attended a seminar on the last year’s changes to trademark law in China. There was a nice bonus at the end, though, in the form of a discussion of patent litigation trends from Wan Hui Da…

30 April 2015

New Senate bill pushes patent reform a step closer to consensus, but there is a long way to go

The latest attempts to introduce new legislative patent reform in the US took its most significant step yesterday when the Protecting American Talent and Entrepreneurship (PATENT) Act was introduced in the Senate. With the backing of Senate…

28 April 2015

Indian businesses crave IP certainty, but better patent values are tempting them overseas

Indian corporate leaders view a strong and sustainable IP system as key to furthering their country’s economic development and attracting continued foreign investment, a recent study suggests. A lack of confidence that this is currently the case –…

23 April 2015

Buying time, quality over quantity, the gathering litigation storm and more from IPBC China 2015

There were over 250 attendees at a packed-to-the-rafters IPBC China, which took place this week at the Shangri-La Hotel in Haidian, Beijing. Delegates, mostly local IP professionals working inside major Chinese businesses, participated in a series…

09 April 2015

If pharma has high-quality patents IPRs should not be an issue, says hedge fund investor

Perhaps the patent story of the year so far has been the inter partes reviews (IPR) launched at the Patent Trial and Appeal Board (PTAB) against a series of pharmaceutical patents by hedge fund investors. Kyle Bass, founder of Hayman Capital…

19 January 2015

Hammering “trolls” harms US prosperity, says top BASF IP strategist

US legislators have arrived back on Capitol Hill with patent reform again firmly on the agenda. Congressman Bob Goodlatte, chairman of the House of Representatives Judiciary Committee and author of the Innovation Act in the last Congress, has made…